If one disease captures the essence of an emerging disease, it is dengue—viral in origin, highly epidemic-prone, and for decades without an effective vaccine. Its trajectory is a warning signal for global health: from being confined to fewer than seven countries in the 1960s, dengue has now entrenched itself in more than 130 countries across Asia, Africa, and the Americas. About half of the world’s population is now at risk of dengue, with an estimated 100–400 million infections occurring each year. Today, approximately 3.6 billion people live in areas at risk of transmission. This explosive expansion reflects not only the adaptability of its mosquito vector but also the inadequacy of public health systems to prevent its spread. The rise of dengue illustrates how climate change, urbanization, globalization, and weak political commitment converge to transform a once-localized infection into a worldwide threat. The most compelling themes that capture the essence of dengue include its unique biological nature, the extraordinary efficiency of its mosquito vector, the profound complexities surrounding vaccine development, and the decisive influence of political will.1 Dengue holds a distinct place among mosquito-borne diseases because of its intricate virological and immunological characteristics. Unlike many other arboviral infections, it is caused by four distinct serotypes of the dengue virus, each capable of producing disease with an unpredictable clinical course. A primary infection may present with relatively mild symptoms, yet a subsequent infection with a different serotype can trigger severe and potentially fatal illness through a phenomenon known as antibody-dependent enhancement (DAE). The absence of specific antiviral treatment and the limited availability of effective vaccines further compound the challenge of managing dengue. This combination of factors—its serotypic diversity, immunological, clinical unpredictability, and restricted preventive tools—establishes dengue as a truly distinctive and formidable disease within the field of epidemic-prone diseases. The development of dengue vaccines presents a unique immunological dilemma that sets them apart from most other immunization efforts. Unlike vaccines for diseases such as polio or measles, where protection is broad and straightforward, dengue vaccines must navigate intricate immunological challenges. Their effectiveness is greatest in individuals who have already experienced a prior dengue infection, while in those who are dengue-naïve, vaccination may paradoxically increase the risk of severe disease due to immune mechanisms such as DAE. This unusual interplay between immunity and risk makes dengue vaccination one of the rare instances in medical history where scientific innovation collides with profound biological complexity, highlighting the exceptional challenges of preventing this disease through immunization. Dengue vaccine development faces major challenges due to the virus’s four serotypes and risk of DAE. The licensed vaccines—Qdenga (TAK-003) and Dengvaxia (CYD-TDV)—offer only partial and serotype-specific protection, with reduced efficacy in people not previously exposed to dengue. The live-attenuated vaccine TAK-003 (Qdenga) shows promise with 80% initial efficacy against dengue-virus-serotyp 2 (DENV-2), but its declining effectiveness over time and limited utility in seronegative individuals raise concerns for regions with fluctuating dengue seroprevalence. This variability calls for tailored immunization programs that consider local serotype circulation and prior exposure rates. The immunological complexity of dengue, including DAE and original antigenic sin, complicates vaccine development. While CYD-TDV (Dengvaxia) demonstrated moderate efficacy (60%), its association with increased hospitalization risks in seronegative individuals limits its widespread use in naïve populations. New candidates like TV-003/TV-005, recombinant subunit, and mRNA vaccines show promise, but affordability, durability, and regional tailoring remain key hurdles.2,3 From another perspective, Aedes aegypti demonstrates an extraordinary efficiency as a vector, owing to its remarkable adaptation to human environments. In many settings, the scarcity and shortage of water force households to store water in containers that are often poorly covered or inadequately managed, inadvertently creating ideal breeding sites. The mosquito readily exploits such environments, thriving in small water-holding vessels such as buckets, tanks, flower pots, and discarded tires. Its eggs are highly resilient, capable of surviving dry periods and reactivating when favorable conditions return, ensuring persistence even through prolonged droughts. Unlike many other mosquito species, A. aegypti is predominantly active during the day, takes multiple blood meals within a single reproductive cycle, and shows a strong preference for human hosts, which greatly enhances transmission efficiency. Furthermore, vertical transmission sustains the virus within mosquito populations across generations. This combination of ecological adaptation, behavioral traits, and environmental drivers makes A. aegypti exceptionally difficult to control and firmly establishes it as the perfect urban vector. Additionally, the expansion of Aedes mosquito vectors is broadening the virus’s geographical distribution, encroaching upon previously unaffected areas, and raising concerns in non-tropical regions about the potential emergence of arboviruses like Dengue in regions traditionally not affected, such as Europe. Efforts to control dengue outbreaks have often relied on interventions that are imperfect or only partially effective. Space spraying “fogging” with insecticides remains a common response, yet its impact is transient, killing only adult mosquitoes present at the time while leaving eggs and larvae untouched. Within days, new generations re-emerge, and the cycle continues. Moreover, A. aegypti tends to rest indoors in hidden sites where sprays may not penetrate effectively, and rising insecticide resistance further undermines results. Other frequently cited measures, such as the use of bed nets for the sick, also illustrate this imperfection. Because A. aegypti is primarily a day-biting mosquito, bed nets provide only partial protection and are often impractical for continuous use during waking hours. Similarly, calls to make hospitals and treatment facilities “mosquito-free zones” face substantial challenges in resource-limited contexts, where inadequate infrastructure, poor screening, and insufficient vector control inside buildings allow mosquitoes to persist. These interventions, while not without value, highlight the difficulty of relying on fragmented, short-term responses. Without integration into comprehensive, sustained strategies that address breeding sites, water storage practices, and community engagement, such measures remain limited in their capacity to alter the trajectory of outbreaks. Dengue control is as much a matter of governance as it is of science. While effective technical solutions exist—including integrated vector management, robust surveillance, improved water storage practices, and timely clinical care—outbreaks continue to recur in settings where political will is weak, fragmented, or driven by short-term priorities. In the absence of an effective dengue vaccine, vector control remains the cornerstone of prevention. Singapore’s experience highlights that success depends on data-driven, regionally coordinated strategies grounded in continuous epidemiologic and entomologic surveillance rather than reactive case responses. Reactive interventions typically begin only after clinical cases are detected, by which time secondary infections have already occurred, limiting their effectiveness. In contrast, proactive, sustained surveillance and early vector control are far more effective in interrupting transmission. Even with low A. aegypti indices, imported infections and waning population immunity continue to increase dengue transmission, underscoring the need for comprehensive, and regionally integrated mosquito control programs. Emerging approaches include the release of Wolbachia-infected mosquitoes to block viral transmission, genetic modification technologies to suppress mosquito populations, and integrated environmental management to eliminate breeding habitats. Strengthening regional collaboration through shared surveillance data platforms, harmonized control guidelines, joint training initiatives, and cross-border task forces is essential to achieving sustainable dengue control.4,5 Dengue remains beyond the reach of eradication due to a convergence of biological and ecological challenges. The existence of four distinct viral serotypes, each capable of causing disease and reinfection, complicates the development of lasting immunity at both individual and population levels. Its primary vector, A. aegypti, is exceptionally well adapted to urban environments, thriving in man-made containers and sustaining transmission even in resource-limited settings. Moreover, the remarkable resilience of mosquito eggs, which can survive for months in dry conditions, ensures the persistence of breeding sites and facilitates rapid resurgence once water becomes available. In this context, eradication is not a realistic prospect; rather, the focus must remain on sustained control, risk reduction, and resilience. Dengue, thus, represents a paradigm of public health challenges in which societies must learn to manage and coexist with endemic risk, rather than anticipate its complete elimination. Dengue has evolved into a regional and global public health concern, extending far beyond the confines of local transmission. In the Eastern Mediterranean Region, outbreaks have been repeatedly documented in countries such as Saudi Arabia, Yemen, Sudan, Pakistan, and Djibouti, where rapid urbanization, chronic water shortages, and ongoing conflict create fertile conditions for the disease to spread. The presence of dengue in critical hubs such as seaports, airports, and hospitals amplifies the risk of cross-border transmission, underscoring its potential to move swiftly along pathways of travel and trade. As a result, dengue can no longer be regarded solely as a local or national issue; it is a transnational challenge that demands coordinated regional strategies and sustained global vigilance. Dengue persists and flourishes not solely because of its biological complexity, but also because of the environments of neglect in which it thrives—settings marked by inadequate sanitation, fragile health systems, and weak or inconsistent governance. Conversely, where political commitment is sustained, communities are mobilized, and health systems demonstrate resilience, dengue transmission can be significantly reduced. Ultimately, the greatest obstacle to progress lies not only in the mosquito itself but in our collective failure to act with consistency, coordination, and determination. The global expansion of dengue-endemic regions, including outbreaks in Europe, highlights the urgent need for enhanced surveillance, proactive interventions, and international collaboration to mitigate the growing threat of Dengue.6 In some countries, sustained leadership, consistent investment, and accountability can markedly reduce transmission and mitigate epidemics. These experiences underscore that the decisive factor in dengue control is not the absence of scientific tools but rather the strength and continuity of political commitment to implement them effectively. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.
Hassan El Bushra (Wed,) studied this question.